Sanofi India FY25: Final Dividend ₹48/Share, Rajani Kesari & Sudipta Chakraborty Appointed as Directors
Sanofi India's board approved audited FY25 results and recommended a final dividend of ₹48 per share, in addition to the ₹75 interim dividend. Rajani Kesari was appointed as an Additional and Independent Director for 5 years starting 1st April 2026. Sudipta Chakraborty was appointed as an Additional and Whole-time Director for 3 years starting 1st March 2026. Rodolfo Hrosz resigned as Non-Executive Director effective 28th February 2026.
The changes in the board of directors and the dividend announcement can have a moderate impact on the company's strategic direction and investor sentiment.
The announcement includes positive elements such as the declaration of a dividend and the appointment of new directors, suggesting potential growth and stability.
Sanofi India Limited's Board of Directors convened on 25th February 2026, to discuss and approve the audited financial results for the quarter and financial year ended 31st December 2025. The board has recommended a final dividend of ₹48 per equity share, with a face value of ₹10 each, subject to shareholder approval at the upcoming 70th Annual General Meeting (AGM). This is in addition to the interim dividend of ₹75 per equity share declared on 29th October 2025, bringing the total dividend for the year to ₹123 per equity share. The company will publish the results in the newspapers as per SEBI regulations and make them available on its website. The auditor's report has an unmodified opinion for the financial year ended 31st December 2025. The meeting commenced at 2:00 p.m. and concluded at 5:30 p.m. 25th February 2026.
Mrs. Rajani Kesari has been appointed as an Additional and Independent Director for a 5-year term starting 1st April 2026, subject to shareholder approval. Mr. Rodolfo Hrosz has resigned from his position as Non-Executive Director, effective from the close of business hours on 28th February 2026, due to other commitments. Ms. Sudipta Chakraborty has been appointed as an Additional and Whole-time Director for a 3-year term starting 1st March 2026, also subject to shareholder approval. She will be designated as a Key Managerial Personnel and a Senior Management Personnel of the Company, effective from the said date.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under annual results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.